Chromedx Corp (MNLIF) 0.1800 $MNLIF
ChroMedX Welcomes Dr. Nick Smit to Biosensor Development Team
ACCESSWIRE - Wed Mar 25, 3:56PM CDT
TORONTO, ON / ACCESSWIRE / March 25, 2015 / ChroMedX Corp. (CSE: CHX) (PINKSHEETS: MNLIF) (Frankfurt: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Dr. Nick Smit as part of the HemoPalm biosensor development team.
ChroMedX Appoints Dr. Robert Smyth to Technical Advisory Board
ACCESSWIRE - Tue Mar 24, 3:23PM CDT
TORONTO, ON / ACCESSWIRE / March 24, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the appointment of anesthesiologist Dr. Robert Smyth to the Company's Technical Advisory Board.
ChroMedX Collaborates with Microfluidic and Microfabrication Experts for HemoPalm Cartridge Development
ACCESSWIRE - Mon Mar 23, 3:39PM CDT
TORONTO, ON / ACCESSWIRE / March 23, 2015 / ChroMedX Corp. (CSE: CHX) (PINKSHEETS: MNLIF) (FSE: EIY2) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce it has entered into a collaboration with Dr. Ravi Selvaganapathy of McMaster University to assist in the design and development of prototype cartridges for the Company's patented HemoPalm blood analyzer system.
ChroMedX Submits US Provisional Patent Application for Recently Developed Aspects of HemoPalm Blood Analysis System
ACCESSWIRE - Tue Mar 10, 2:35PM CDT
TORONTO, ON / ACCESSWIRE / March 10, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a second US Provisional Patent Application pertaining to the HemoPalm Cartridge and Analyzer system.
ChroMedX Engages Biosensor Development Expert Stephen Cozzette
ACCESSWIRE - Mon Jan 26, 4:03PM CST
TORONTO, ONTARIO / ACCESSWIRE / January 26, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Mr. Stephen Cozzette as a consultant on the HemoPalm project focussing on the electrochemical sensor and cartridge development aspects of the project.
ChroMedX Exhibits and Presents at Cantech '15 in Toronto, Canada
ACCESSWIRE - Tue Jan 13, 2:46PM CST
Toronto, Ontario / ACCESSWIRE / January 13, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the Company will be presenting and exhibiting at the Cantech '15 Technology Conference on Thursday, January 15, 2015 in Toronto, Ontario Canada.
ChroMedX 2014 Progress Update
ACCESSWIRE - Fri Dec 19, 3:19PM CST
Toronto, ON / ACCESSWIRE / December 19, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is proud to report on the Company's corporate and developmental progress in 2014.
Early Warning News Release of Invidx Corp.
ACCESSWIRE - Mon Dec 15, 9:47AM CST
Toronto, ON / ACCESSWIRE / December 15, 2014 / Invidx Corp. (OTC:MNLIF) (EIY2.F) ("Invidx"

, a company controlled by James Samsoondar, the Chief Science Officer and director of the Company, announces that it has acquired ownership and control of 5,474,452 common shares of ChroMedX Corp. (the "Company" or "ChroMedX"

through the exercise of an ultrafiltration option by ChroMedX. Prior to this acquisition, Invidx held 15,000,100 common shares of ChroMedX.
Chromedx Completes Acquisition of Automated Ultrafiltration Immunoassay Technology
ACCESSWIRE - Mon Dec 15, 5:37AM CST
Toronto, Ontario / ACCESSWIRE / December 15, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the it has closed its previously announced acquisition of patent application PCT/CA2013/050935 related to Automated Ultrafiltration Technology and associated intellectual property ("AUF"

from InvidX Corp., pursuant to an option agreement dated June 16, 2014 (the "Option Agreement"

. As consideration for the acquisition of the AUF the Company has issued 5,474,452 common shares to InvidX Corp. which was determined based on the 20% discount to the 10-day volume weight average price of the Company's shares immediately preceding the date of exercise of the option as per the terms of the Option Agreement.
ChroMedX Commences AUF Development with Aline Inc. and Spectrum Labs
ACCESSWIRE - Tue Dec 09, 3:37PM CST
TORONTO, ON / ACCESSWIRE / December 9, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"

, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of ALine Inc. as primary contractor for the development of its recently acquired Automated Ultrafiltration (AUF) Cartridge.